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Background: There is growing evidence that the ghrelin axis, including ghrelin (GHRL) and its receptor, the growth
hormone secretagogue receptor (GHSR), play a role in cancer progression. Ghrelin gene and ghrelin receptor gene
polymorphisms have been reported to have a range of effects in cancer, from increased risk, to protection from cancer,
or having no association. In this study we aimed to clarify the role of ghrelin and ghrelin receptor polymorphisms in
cancer by performing a meta-analysis of published case–control studies.
We conducted searches of the literature published up to January 2013 in MEDLINE using the PubMed search engine.
Individual data on 8,430 cases and 14,008 controls from six case–control studies of an all Caucasian population were
evaluated for three ghrelin gene (GHRL; rs696217, rs4684677, rs2075356) and one ghrelin receptor (GHSR; rs572169)
polymorphism in breast cancer, esophageal cancer, colorectal cancer and non-Hodgkins lymphoma.
Results: In the overall analysis, homozygous and recessive associations indicated that the minor alleles of rs696217 and
rs2075356 GHRL polymorphisms conferred reduced cancer risk (odds ratio [OR] 0.61-0.78). The risk was unchanged for
breast cancer patients when analysed separately (OR 0.73-0.83). In contrast, the rs4684677 GHRL and the rs572169 GHSR
polymorphisms conferred increased breast cancer risk (OR 1.97-1.98, p = 0.08 and OR 1.42-1.43, p = 0.08, respectively).
All dominant and co-dominant effects showed null effects (OR 0.96-1.05), except for the rs572169 co-dominant effect,
with borderline increased risk (OR 1.08, p = 0.05).
Conclusions: This study suggests that the rs696217 and rs2075356 ghrelin gene (GHRL) polymorphisms may protect
carriers against breast cancer, and the rs4684677 GHRL and rs572169 GHSR polymorphisms may increase the risk
among carriers. In addition, larger studies are required to confirm these findings.
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It is appreciated that ghrelin and its receptor (members
of the ghrelin axis) play a role in the development and
progression of cancer [1]. Ghrelin, the endogenous lig-
and for the growth hormone secretagogue receptor
(GHSR), has many functions, including a role in regulat-
ing growth hormone release [2] and a range of metabolic
effects: regulating appetite, and influencing insulin and
glucose homeostasis, energy balance and adipogenesis
[3,4]. Given the metabolic effects of ghrelin, the ghrelin* Correspondence: npabalan@alumni.yorku.ca
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unless otherwise stated.axis is a promising target for interventions for obesity
and diabetes mellitus type two [5].
There is growing evidence that obesity and metabolic
syndrome is associated with endocrine related cancers
[6] and that the ghrelin axis may play a role in cancer
progression [1]. A mechanistic link has been hypothe-
sised between obesity, ghrelin and the development of
colorectal [7] and prostate cancer [8]. A number of stud-
ies have linked single nucleotide polymorphisms (SNPs)
in the ghrelin (GHRL) or ghrelin receptor (GHSR) genes
with cancer risk [1]. Here, we perform a meta-analysis of
case–control studies that have correlated ghrelin and
GHSR gene polymorphisms with cancer risk to elucidate
further the association between ghrelin axis gene poly-
morphisms and cancer.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data sources
Using PubMed, a literature search was performed for
all association studies (available until January 2013) in-
vestigating links between cancer and the ghrelin
(GHRL) and ghrelin receptor (GHSR) genes. Previous
studies reporting Caucasian genotypic data with case–
control designs were chosen as eligible for this meta-
analysis. In the first search, we used the terms,
“ghrelin”, “polymorphism” and “cancer” which yielded
11 citations, five of which were excluded. From ab-
stracts of the remaining six, one was excluded as it de-
scribed an Asian population. Full texts of the remaining
five studies were obtained, all of which complied with
our inclusion criteria. In the second search, we entered
the terms, “GHRL” and “cancer” in PubMed yielding 13
citations. A series of exclusions reduced the number to
seven, full-texts of which were retrieved. We checked
the reference lists of the full-text articles from both
searches to minimize the possibility of missing relevant
studies. Of the seven studies, six were either duplicated
by the first search, or lacked genotype data, and there-
fore, only one further article was suitable for inclusion.
Combining outcomes from the two searches gave a
total of six articles which were included in our meta-
analysis [9-14].
Data extraction and power calculations
Two investigators independently extracted data and
reached a consensus regarding all information. The fol-
lowing information was obtained from each publication:
first author’s name, published year, country of origin,
dominant ancestry of the study populations, state of con-
trols, matching criteria, sample source, genotype data,
number of cases and controls. We also calculated frequen-
cies of the variant allele, deviations of controls from the
Hardy-Weinberg equilibrium (HWE) and the statistical
power of each study. Assuming an odds ratio (OR) of 1.5
at a genotypic risk level of α = 0.05 (two-sided), power was
considered to be adequate at ≥80%.
Meta-analysis
The strength of association between the ghrelin poly-
morphisms and cancer risk was measured by odds ra-
tios (ORs) with 95% confidence intervals (CIs). Pooled
estimates of the OR were obtained by calculating a
weighted average of OR from each study [15]. For the
following genetic models using variant (var) and wild-
type (wt) genotypes we estimated: (i) additive: (var-var,
var-var and wt-wt) genotypes compared with the wt-wt,
(ii) co-dominant: frequency of variant alleles, assuming
the risk could differ across all three genotypes, (iii) re-
cessive (var-var vs. wt-var + wt-wt) and (iv) dominant:
(var-var + wt-var vs. wt-wt).To compare effects on the same baseline, we used raw
data for genotype frequencies to calculate pooled ORs,
which were obtained using either the fixed effects model
[16], in the absence of heterogeneity, or random effects
model in the presence of heterogeneity [17]. Heterogen-
eity between studies was estimated using the χ2-based Q
test [18]. Given the low power of this test [19], signifi-
cance threshold was set at P = 0.10. Heterogeneity be-
tween studies was estimated using the χ2-based Q test
[18] and quantified with the I2 statistic which measures
degree of inconsistency among studies [20]. Sensitivity
analysis, which involved omitting one study at a time
and recalculating the pooled OR, was also used to test
for robustness of the summary effects. Data were ana-
lyzed using Review Manager 5.3 (Copenhagen: Nordic
Cochrane Centre, Cochrane Collaboration) [21] and Sig-
maStat 2.3 (Systat Software, San Jose, CA). Significance
was set at a P-value of ≤0.05 throughout, except in het-
erogeneity estimation. Publication bias was not investi-
gated because of the low sensitivity of the qualitative
and quantitative tests when the number of studies is
lower than ten [22].Results
Included studies
A total of six genotyping studies [10-14,23] were in-
cluded in the meta-analysis (Figure 1). The study
features, which include nine ghrelin (GHRL) or ghrelin
receptor (GHSR) single nucleotide polymorphisms (SNPs),
the cancer type (breast, colorectal, esophageal and non-
Hodgkin’s lymphoma) and study sample sizes, are outlined
in Table 1. An overview of the ghrelin and ghrelin recep-
tor SNPs examined are shown in Figure 2. Analyses of the
pooled ORs revealed that five (rs495225, rs35684, rs27647,
rs26802 and rs35683) of the nine SNPs investigated exhib-
ited null effects in all genetic models (data not shown).
The remaining three ghrelin SNPs (rs696217, rs4684677,
rs2075356) and one GHSR SNP (rs572169) showed effects
other than null, and were examined further. The features
of these four SNPs (in six different studies), which in-
cluded cancer type (breast, colorectal, esophageal, and
non-Hodgkin’s lymphoma), ethnicity, number of cases
and controls, calculated statistical power, minor allele fre-
quency (MAF) and HWE are summarised in Table 2. The
studies, that included rs696217 [10-14,23], rs4684677
[10-13], rs2075356 [11,12,23] and rs572169 [11,14,23] had
statistical power of >83%, indicating that these studies
were not underpowered (Table 2). Control frequencies in
two component studies [10,14] deviated from the HWE in
the rs4684677 and rs572169 polymorphisms (Table 2).
Furthermore, three studies demonstrated borderline devi-
ation from the HWE (p = 0.05-0.06) for the rs69621,
rs2075356 and rs572169 polymorphisms [10,11,23].
Figure 1 Flowchart of literature search.
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The overall effects (odd ratios) for the three GHRL
polymorphisms (rs696217, rs4684677, rs2075356) and
the rs572169 GHSR polymorphism, and the effects ob-
served in breast cancer studies alone are shown in Table 3.Table 1 The nine GHRL/GHSR polymorphisms examined in the
cancer samples and sample sizes
N studies
Polymorphism References Cancer type
BC CRC E
1 GHRL 696217 [10-14,23] 3 1 1
2 GHRL 4684677 [10-12,23] 2 1 1
3 GHRL 27647 [11,12,23] 2 2 0
4 GHRL 26802 [11,12,23] 2 1 0
5 GHRL 2075356 [11,12,23] 2 1 0
6 GHRL 35684 [11,13,23] 1 1 0
7 GHRL 35683 [12,23] 1 2 0
8 GHSR 495225 [11,14,23] 2 1 0
9 GHSR 572169 [11,14,23] 2 1 0
Studies have examined ghrelin gene (GHRL) or ghrelin receptor gene (GHSR) polymorp
Non-Hodgkin’s Lymphoma (NHL) [10-14,23].
SNPs in bold were examined in more detail in the current study.Associations were observed mainly in the homozygous
and recessive models and not in the dominant model,
where the effects were null (OR 0.90-1.05, p = 0.19-
0.92). Non-significant, decreased risks associated with
the rs696217 (OR 0.61-0.63, p = 0.09-0.11) GHRLmeta-analysis, the number of studies performed in
Number of
C NHL Total Cases Controls Total
1 6 3,601 6,101 9,702
0 4 2,888 4,938 7,826
0 4 2,512 3,709 6,221
0 3 1,958 2,994 4,952
0 3 1,941 2,972 4,913
1 3 2,144 3,480 5,624
0 3 1,864 1,949 3,813
0 3 2,350 3,370 5,720
0 3 2,378 3,414 5,792
hisms in breast cancer (BC); colorectal cancer (CRC); esophageal cancer (EC); and
Figure 2 Schematic diagram of the genes encoding ghrelin
(GHRL) and the ghrelin receptor (GHSR). Exons are shown as
boxes, introns as lines. The canonical coding exons of GHSR1a
(cognate ghrelin receptor; GHSR) and ghrelin (GHRL) are shown as
black boxes. Exon I and II (white boxes) are unique to the GHRL
splice variant in2c-ghrelin. The SNPs examined in this study
are indicated.
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rectal cancer were not altered when analyses were
confined to breast cancer studies alone (OR 0.82-0.83, p =
0.57-0.60) (Table 2). For rs696217, all of the study-specific
ORs indicate reduced risk (Figure 3) and one study [11] in
particular had a one-third weight contribution (33.5%) toTable 2 Characteristics of the four GHRL/GHSR polymorphism
(CRC), esophageal cancer (EC) and Non-Hodgkin’s Lymphoma
Number of
First author (year) Ethnicity Cancer type Cases C
rs696217 Leu72Met GHRL exon 3
Dossus [11] Europe Breast 1,324 2
Feigelson [12] USA Breast 639 6
Wagner [14] Europe Breast 395 4
Campa [23] Europe CRC 678 6
Doecke [10] Australia EC 260 1
Skibola [13] USA NHL 305 6
rs4684677 Gln90Leu GHRL exon 4
Dossus [11] Europe Breast 1,311 2
Feigelson [12] USA Breast 634 6
Campa [23] Europe CRC 683 6
Doecke [10] Australia EC 260 1
rs2075356 3056 T > C GHRL intron 3/in2c ghrelin 3’UTR
Dossus [11] Europe Breast 634 1
Feigelson [12] USA Breast 640 6
Campa [23] Europe CRC 667 5
GHSR rs572169 Gly57Gly GHSR exon 1
Dossus [11] Europe Breast 1,327 2
Wagner [14] Europe Breast 402 4
Campa [23] Europe CRC 649 5
Minor allele frequency (MAF); Hardy-Weinberg Equilibrium (HWE). UTR = untranslatethe pooled effect (OR 0.63, p = 0.11). Similarly, a non-
significant decrease in the risk of the GHRL polymorph-
ism, rs2075356, in breast and colorectal cancer (OR 0.78,
p = 0.43-0.45) was unaltered when confined to breast can-
cer studies (OR 0.78, p = 0.43-0.45) (Table 2). Increased
risk in the GHRL SNP rs4684677 (OR 1.97-1.98, p = 0.08)
associated with breast and esophageal cancers was exacer-
bated when confined to breast cancer (OR 2.38-2.40, p =
0.06). Figure 4 shows the contributions of study-specific
ORs to the homozygous increased risk pooled effect of
rs4684677 (OR 1.98, p = 0.08), mostly (60.6%) attributed
to Dossus et al. [11]. On the other hand, the minimal
weight contribution (5.3%) of the study by Feigelson et al.
[12] is accompanied by wide confidence intervals (95% CI
0.49-169.90). The increased risk associated with the GHSR
SNP rs572169 in breast and colorectal cancer (OR 1.42-
1.43, p = 0.08) was also increased only when breast cancer
was considered (OR 1.69-1.70, p = 0.14). While all of these
effects of GHRL SNPs were obtained in zero heterogeneity
(I2 = 0%), the effect of rs572169 was heterogeneous (I2 =
68-81%). Figure 5 shows heterogeneity (I2 = 68%) of the
rs572169 increased risk pooled effect (OR 1.42, p = 0.08).
Increased risks were also observed in the co-dominant
model of breast cancer studies for the rs4684677 GHRLs in six studies in breast cancer (BC), colorectal cancer
(NHL)
ontrols Total Power
(α = 0.05, OR = 1.5)
MAF HWE
,360 3,684 99.9 0.08 0.81
49 1,288 94.8 0.08 0.76
56 851 82.8 0.08 0.84
00 1,278 94.6 0.07 0.05
,352 1,612 83.9 0.08 0.05
84 989 82.7 0.08 0.59
,339 3,650 99.9 0.06 0.78
47 1,281 94.7 0.05 0.14
00 1,283 94.6 0.07 0.83
,352 1,612 83.9 0.06 0.02
,734 2,368 99.1 0.09 0.93
52 1,292 94.9 0.10 0.72
83 1,250 94.1 0.08 0.05
,368 3,695 99.9 0.27 0.06
58 860 83.2 0.26 0.004
88 1,237 93.9 0.28 0.77
d region.
Table 3 Summary odds ratios (OR) of associations between four ghrelin/GHSR gene polymorphisms with cancer using
four genetic models (homozygous, dominant, recessive and co-dominant) in all studies analysed and in breast cancer
studies alone
Homozygous Recessive Dominant Co-dominant
N OR (95% CI)
P value
Phet I
2 OR (95% CI)
P value
Phet I
2 OR (95% CI)
P value
Phet I




rs696217 6 0.63 (0.36-1.11) 0.11 0.82 0 0.61 (0.35-1.08) 0.09 0.77 0 0.98 (0.87-1.11) 0.79 0.17 36 0.96 (0.86-1.07) 0.49 0.37 8
rs696217a 3 0.82 (0.41-1.62) 0.57 0.87 0 0.83 (0.42-1.65) 0.60 0.87 0 0.90 (0.78-1.05) 0.19 0.99 0 0.91 (0.79-1.04) 0.18 0.97 0
rs4684677 3 1.98 (0.92-4.26) 0.08 0.46 0 1.97 (0.92-4.24) 0.08 0.46 0 1.00 (0.86-1.16) 0.98* 0.28 22 1.02 (0.89-1.18) 0.75 0.28 23
rs4684677a 2 2.40 (0.98-5.86) 0.06 0.29 10 2.38 (0.97-5.81) 0.06 0.28 13 1.08 (0.90-1.30) 0.39 0.37 0 1.11 (0.94-1.32) 0.23 0.50 0
rs2075356 3 0.78 (0.41-1.47) 0.45 0.95 0 0.78 (0.41-1.46) 0.43 0.96 0 1.02(0.88-1.20) 0.76 0.58 0 1.02 (0.88-1.18) 0.79 0.56 0
rs2075356a 2 0.73 (0.33-1.62) 0.43 0.97 0 0.73 (0.33-1.62) 0.43 1.00 0 0.99 (0.83-1.19) 0.92 0.45 0 0.99 (0.84-1.18) 0.93 0.38 0
rs572169 3 1.42 (0.95-2.13) 0.08 0.04R 68 1.43 (0.95-2.14) 0.08 0.03R 70 1.05 (0.94-1.16) 0.40 0.82 0 1.08 (1.00-1.18) 0.05 0.34 7
rs572169a 2 1.69 (0.84-3.41) 0.14 0.02R 81 1.70 (0.84-3.44) 0.14 0.02R 82 1.05 (0.93-1.18) 0.46 0.53 0 1.10 (1.00-1.21) 0.05 0.17 46
abreast cancer only; N: number of studies; *N = 4; OR: odds ratio; CI: confidence interval; Phet: P value for heterogeneity; the meta-analysis was conducted using
the fixed-effects model unless otherwise stated; Rrandom-effects model (Bold indicates increased risk).
I2 values as measure of heterogeneity are considered low (<44%), moderate (45-74%) or high (>75%).
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both overall and in breast cancer (OR 1.08-1.10), with
borderline significance (p = 0.05), all homogeneously ob-
tained (I2 = 0-46%).
Omitting the studies that deviated from HWE (in-
cluding those at borderline level) did not materially
alter the original summary effects for all four polymor-
phisms (data not shown). Sensitivity analysis did not
alter the effects of the rs4684677 and rs2075356 GHRL
polymorphisms. Removal of the Dossus et al. [11]
breast cancer study generated a significant protective
effect of the GHRL SNP rs696217 in the recessive
model (OR 0.46, 95% CI 0.21-0.97, p = 0.04). The
omission of the breast cancer study by Feigelson et al.
[12] erased heterogeneity for the GHSR SNP rs572169
(from I2 = 68% to 0%), but left the pooled OR materi-
ally unchanged.
Discussion
With a combined sample size of 22,438 (8,430 cases and
14,008 controls), this meta-analysis provides evidence ofFigure 3 Forest plot of homozygous pooled effect in the rs696217 po
indicate the OR in each study, with square sizes directly proportional to the
confidence intervals.overall homozygous and recessive associations, indicating
a ~2-fold non-significant increase in cancer risk for the
GHRL SNP rs4684677 and a ~1.4-fold non-significant in-
creased risk for the GHSR SNP rs572169. This GHSR
polymorphism showed a ~1.1-fold increased risk, with
borderline significance in the co-dominant model. In con-
trast, the rs696217 and rs2075356 GHRL polymorphisms
were both protective (22% and 38%), suggesting linkage
disequilibrium (D’ = 0.90, r2 = 0.45) between the two SNPs
[24]. The strength of these associations lie in the follow-
ing: (i) they were obtained in total homogeneity under-
lying the statistical similarity of the component studies; and
(ii) sensitivity analysis did not materially alter the effects
underlying robustness of the pooled ORs. Interestingly,
both the rs696217 (Leu72Met) and rs4684677 (Gln90Leu)
GHRL SNPs have been linked with obesity [25,26]. There is
growing recognition that obesity is a risk factor for a num-
ber of cancers, including breast, endometrial, colorectal,
esophageal and prostate cancer [1].
The GHRL rs2075356 (3056 T > C) and GHSR rs572169
(Gly57Gly) SNPs were found to be associated with 20%lymorphism. Black diamond denotes the pooled OR. Blue squares
weight contribution (%) of the study. Horizontal lines represent 95%
Figure 4 Forest plot of homozygous pooled effect in the rs4684677 polymorphism. Black diamond denotes the pooled OR. Blue squares
indicate the OR in each study, with square sizes directly proportional to the weight contribution (%) of the study. Horizontal lines represent 95%
confidence intervals. Note that case–control values for Doecke et al. [10] were non-estimable and therefore not included in the forest plot.
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1,324 cases and 2,360 controls [11]. These findings were
similar in our meta-analysis, which included an additional
2,227 cases and 3,741 controls, for rs572169 with 1.7-fold
increased breast cancer risk, however, rs2075356 was 27%
protective in our meta-analysis. Ghrelin and ghrelin recep-
tor are expressed in breast cancer tissue and ghrelin could
play a role in breast cancer progression [1,27,28]. Interest-
ingly, the GHRL SNP rs2075356 is present within the 3′
untranslated region of the recently discovered ghrelin
transcript in2c-ghrelin, which is expressed in breast tu-
mours, but not in normal breast tissue [8]. In2c-ghrelin is
predicted to encode a novel 83 amino acid preprohor-
mone that codes for the 28 amino acid ghrelin peptide
(encoded by exon 1 and 2), but not obestatin (encoded by
exon 3) [8]. Depending on the cell-type, obestatin has
growth promoting or suppressing functions [29], however,
the function of this peptide in breast cancer remains to be
determined. The in2c transcript is insulin-regulated in
prostate [8] and breast cancer cell lines (data not shown).
Breast and prostate tumour cells are responsive to insulin
[30-32], and elevated insulin (hyperinsulinaemia) is associ-
ated with breast and prostate cancer risk [33,34].
Strengths and weaknesses
Each of the six component studies in our meta-analysis
examined multiple polymorphisms of ghrelin and its re-
ceptors. The multiplicity of calculations involved necessi-
tated statistical adjustment to avoid false-positive findings.
All six studies were adjusted for multiple testing. Three
used the conservative Bonferroni correction [10,12,23],
one used the false positive report probability [11] and theFigure 5 Forest plot of homozygous pooled effect in the rs572169 po
indicate the OR in each study, with square sizes directly proportional to the
confidence intervals.fifth used the less conservative false discovery rate [13].
The sixth study did not test for multiplicity, but compared
risk SNPs with a corresponding cohort study [14].
These correction procedures, as well as the afore-
mentioned features of the cases and controls in the
component studies, reflect the overall strength of this
meta-analysis. Other strengths of this study include: (i)
ethnic homogeneity of the subjects given our focus on
Caucasians only, resulting in minimal admixture and
control for potential effects of population stratification;
(ii) high sample sizes translating to robust statistical
power of the component studies; (iii) statistical homo-
geneity in the comparisons, so that data in the included
studies were similar enough to be pooled. Moreover,
(iv) findings in the breast cancer subgroup were ob-
tained in zero heterogeneity; (v) controls were either
healthy or cancer-free and were matched to cases; (vi)
tissue sources were blood; and (vii) all component stud-
ies were population-based which minimizes effects of
selection bias, such that findings may be extrapolated
to the general population. Nonetheless, limitations that
need to be acknowledged are: (i) lack of representation
in the various cancers (except breast cancer) disallowed fur-
ther subgroup comparisons; and (ii) deviation from HWE
among controls of Skibola et al. [13] and Wagner et al. [14]
in the rs4684677 and rs572169 SNPs, respectively.
Conclusions
In summary, our results indicate that GHRL and GHSR
SNPs may be involved in the pathophysiology of breast
cancer. To our knowledge, this is the first meta-analysis
to examine ghrelin polymorphisms and cancer risk. Thelymorphism. Black diamond denotes the pooled OR. Blue squares
weight contribution (%) of the study. Horizontal lines represent 95%
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rs696217 and rs2075356 SNPs) and increased suscepti-
bility (for the rs4684677 and rs572169 SNPs) are de-
rived from high-powered studies and are likely to
increase the detection of low-penetrant effects. Further
studies with larger and more well-defined sample popu-
lations are warranted to verify the role of GHRL and
GHSR polymorphisms in cancer. This includes the ana-
lysis of additional metabolic, genetic and environmental
contexts, which would be expected to influence the pa-
tient phenotype.
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